Market reactionShares fell 10% on Nov 5.
Sana Biotechnology is a clinical-stage company engineering cells as medicines, led by SC451, a stem cell-derived islet cell therapy for type 1 diabetes; none of its products is approved.
Sana's case rests on hypoimmune (HIP) gene edits that let transplanted cells escape immune attack. In one patient with type 1 diabetes, HIP-edited donor islets (UP421) made insulin for 14 months without immunosuppression. SC451 applies the same edits to stem cell-derived islets, and Sana plans an IND and Phase 1/2 start as early as 2026. SG293, which makes CAR T cells inside the body, could report first human data in lymphoma as early as 2026. Cash of $160.5 million lasts into mid-2027.
Thesis checklist
1 risk needs attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: SC451 enters the clinic
Does Sana file the SC451 IND and begin dosing patients with type 1 diabetes on schedule?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Sana aims to start testing SC451 islet cells in type 1 diabetes this year
UP421 human proof-of-concept without immunosuppression positions SC451, but cash runway into 2027 may not survive to clinical readout
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Blood cancers, Obesity, diabetes and heart disease, Autoimmune and inflammatory diseases
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
12 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.